Canaloplasty vs trabeculectomy for primary glaucoma
Session Details
Session Title: Glaucoma II
Session Date/Time: Monday 12/09/2016 | 08:00-10:30
Paper Time: 09:50
Venue: Hall C4
First Author: : P.Santorum ITALY
Co Author(s): : M. Simonazzi E. Bertelli
Abstract Details
Purpose:
To compare the results of canaloplasty and trabeculectomy to treat elevated intraocular pressure (IOP) in primary open angle glaucoma (POAG), pseudoexfoliation glaucoma (PEXG), and pigmentary glaucoma (PIG).
Setting:
“San Maurizio” Regional Hospital, Bolzano, Italy. Secondary Referral, Non-Academic, National Health System Hospital.
Methods:
Retrospective non-randomized comparative case series. The charts of 132 eyes that underwent glaucoma or combined glaucoma-cataract surgery between 2011 and 2015 were reviewed. Inclusion criteria were diagnosis of POAG, PEXG or PIG, treated by either trabeculectomy with mitomycin (TE) or suture-based canaloplasty (CP). Exclusion criteria were previous surgery other than non-complicated clear-corneal phacoemulsification and follow-up of < 3 months. Outcomes were classified at the latest follow-up visit as complete success (IOP <19 without medications), qualified success (IOP <19) or failure (IOP >18 or reoperation for uncontrolled IOP). Glaucoma medication use, complications, additional interventions and length of hospital stay were recorded.
Results:
Eighty-seven eyes (52 TE and 35 CP) were included. Respectively in the TE and CP group, complete success was achieved in 24 (46%) and 25 (75%), qualified success in 40 (94%) and 33 (94%) and failure in 3 (6%) and 1 (3%) eye. Mean glaucoma medication use was 1.1 and 0.4 medication, mean hospital stay was 5.2 and 2.4 nights, and additional interventions were required in 20 (38%) and 2 (6%) eyes. The most common complication was choroidal detachment in the TB group (9 eyes 19%) and hyphema (9 eyes 26%) in the CP group.
Conclusions:
Both TE and CP were safe and effective in lowering IOP in primary glaucoma. Although IOP control was comparable, TE eyes required more surgical reinterventions, more postoperative medications, and longer hospital stay.
Financial Disclosure:
NONE